New Maryland facility adds 60,000 liters of drug substance capacity, boosting total to 845,000 liters
Samsung Biologics has officially announced the acquisition of a biopharmaceutical manufacturing plant in Rockville, Maryland, marking its first production site in the United States. This strategic expansion strengthens Samsung Biologics’ position as a leading global CDMO.
The South Korean contract development and manufacturing organization (CDMO) finalized the $280 million deal to acquire GSK’s Rockville plant, initially announced in December. The new site includes two Current Good Manufacturing Practice (cGMP)-certified manufacturing facilities, offering a combined 60,000-liter drug substance capacity. This addition enhances Samsung Biologics’ capabilities in clinical and commercial biologics production across various manufacturing scales, increasing its total global manufacturing capacity to 845,000 liters.
“This acquisition represents a significant step in expanding our US manufacturing presence,” stated John Rim, CEO of Samsung Biologics. “The addition of the Rockville site strengthens our geographically diversified manufacturing network, and we are excited to welcome over 500 new colleagues to the Samsung Biologics family.”
“The Rockville team brings invaluable expertise and operational experience, further enhancing the site’s capabilities within our global manufacturing network. As a dedicated CDMO, our primary goal is to support our partners in delivering vital therapies to patients worldwide. This new site will play a crucial role in achieving this mission, ensuring seamless continuity and maintaining the high standards our clients expect.”
Under the terms of the agreement, Samsung Biologics will continue to manufacture GSK’s existing products at the Rockville site. Simultaneously, the company will transition the facility to accommodate additional contract manufacturing projects. Samsung Biologics also plans to invest in expanding the site’s capacity and upgrading its technologies, reinforcing its long-term dedication to building a more robust global supply chain and improving patient access to essential medicines.
hwkan
